Preventing HIV transmission with a daily pill regimen

Daily Xtra's comprehensive PrEP coverage kicks off Feb 3

Can a pill a day stop the transmission of HIV? Some early studies on the efficacy of pre-exposure prophylaxis (PrEP) say yes. But few gay men are taking this pill therapy. Why? Is this the miracle and prevention we have all been waiting for or another false start in the fight against HIV?

Can a pill a day keep HIV away? Some early studies say yes.

Pre-exposure prophylaxis (PrEP) is an HIV medication that can be taken to reduce the possibility of HIV transmission. In the United States in 2012, the FDA (Food and Drug Administration) approved the use of Truvada, a drug commonly used with other antiviral medications in the treatment of HIV, for use as a preventative medication.

It was a ground-breaking decision at the time, but few gay men are taking the pills.

Daily Xtra will kick off a comprehensive series on PrEP, including a four-part video report, on Feb 3. What is PrEP? How does it work? Why are so few people taking it? Is it legal in Canada? And what are the implications of providing gay men who don’t use condoms protection from HIV?

Join the discussion on our Facebook page, Twitter account and on our YouTube channel.

Read More About:
Health, Video, News, HIV/AIDS, Ottawa, Toronto, Canada

Keep Reading

Advocates mount new challenge to Alberta anti-trans law

Skipping Stone and Egale Canada are headed back to court to try and overturn Alberta’s youth gender-affirming-care ban

Dylan Mulvaney’s Broadway debut is about more than the backlash

Mulvaney’s casting in “SIX: The Musical” is the latest example of Broadway platforming trans stars
A side by side of Radclyffe Hall and her lesbian novel The Well of Loneliness, with was subject to censorship and obscenity laws

Inside the censorship campaign against this 20th century lesbian novel

Radclyffe Hall’s “The Well of Loneliness” was the target of obscenity laws in 1928

Publishers are acquiring fewer queer books due to U.S. book bans: Report

LGBTQ2S+ authors say they are seeing increases in rejections from publishers and significant decreases in royalties